Population
Mast cell-deficient (Kit(w)/Kit(w-v)) mice and their mast cell-sufficient littermate (MC(+/+)) controls
Comparison
Acute ACE inhibition plus AT(1) receptor blockade vs ACE inhibition alone
Design
Preclinical
Authors
Loading...
Suggests mast cell-targeted strategies for hypertension; leaves open translation of dual ACEi/ARB benefit to humans.
Mast cells are the source of the vascular ACE-independent pathway for Angiotensin II generation, providing a mechanistic rationale for the antihypertensive benefit of combining ACE inhibitors with AT1 receptor antagonists.
Li et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: